Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics

48-week,Multinational,Randomized,Double-blind,2-parallel Groups,Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics >=18 Years of Age

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00861926

Enrollment

2079

Registered

2009-03-16

Start date

2009-03-31

Completion date

2011-04-30

Last updated

2017-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Maintenance and Reliever Treatments

Brief summary

Double-blind, multinational, multicentre, randomized, 2-arm parallel-group study

Detailed description

To compare efficacy of Foster as maintenance therapy plus additional inhalations as reliever with Foster as maintenance plus salbutamol as reliever in asthmatics

Interventions

DRUGVentolin

Ventolin : salbutamol sulfate 100µg

DRUGbeclometasone /formoterol

BDP 100µg/FF 6µg, 1 inhalation bid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Written signed and dated informed consent obtained. * Male or female patients aged ≥ 18 years. * A positive reversibility test * Patients who experienced at least one severe exacerbation in the 12 months before entry (but not in the last month) * Using inhaled corticosteroids (ICS) in monotherapy or using ICS in a fixed or free combination with long acting beta2 agonists (LABA) at a constant dose for two months before screening visit * Not fully controlled asthmatics (which means partly controlled or/and uncontrolled patients according to GINA guidelines 2007) in the last month before screening visit * Forced expiratory volume in the first second (FEV1) ≥ 60% of predicted for the patient normal value. * Non smokers or ex-smokers

Exclusion criteria

* Pregnant or nursing (lactating) women. Women of child-bearing potential UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/mL or are using one or more of acceptable methods of contraception * Body Mass Index (BMI) \> 34 kg/m2. * Patient with lower respiratory tract infections affecting the patient's asthma within 30 days of the screening visit. * Use of systemic steroids in the last month. * Patients with other lung diseases such as COPD, cystic fibrosis, interstitial lung diseases or any other clinically or functionally significant lung disorder. * Patients who have an uncontrolled respiratory, haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease. * Clinically relevant laboratory abnormalities * Patients who have an abnormal QTcF interval value * Intolerance or contra-indication to treatment with beta2-agonists and/or ICS or allergy to any component of the study treatments. * Patients treated with slow-release corticosteroids in the 3 months prior to screening visit. * Patients being treated with anti-IgE antibodies. * Patients treated with LABA or ICS/LABA fixed combination in the 24h before screening visit * Severe asthma exacerbation in the last month before screening visit

Design outcomes

Primary

Measure	Time frame
Time to first severe asthma exacerbation	At each clinic visit

Secondary

Measure	Time frame
Number of severe asthma exacerbations Number of hospitalization Asthma symptoms Rescue medication LFTs	At each clinic visit

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026